Navigation Links
Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
Date:10/29/2009

label, single dose Phase 1 study was initiated in early October and the Company expects to announce results from the trial in the first half of 2010.

Additionally, Amicus continues to be encouraged by the results of preclinical studies designed to evaluate the use of AT2220 in combination with enzyme replacement therapy (ERT). The Company expects to report additional data from these studies at scientific conferences in 2010.

Preclinical Chaperone Programs

Amicus continues to invest in research to assess the potential for applying its versatile chaperone technology platform to the treatment of a broad range of human genetic diseases. As part of this effort, Amicus continues to conduct preclinical studies in Parkinson's disease and is investing in new research aimed at evaluating disease targets for other neurodegenerative and genetic disorders.

Additional Financial Results & Notes

On a reported basis, the net loss attributable to common stockholders for the three months ended September 30, 2009, was $13.4 million as compared to $8.2 million for the same period in 2008. On a non-GAAP basis, the net loss for the three months ended September 30, 2009, was $11.5 million as compared to $6.6 million in the same period in 2008.

Amicus recorded revenue during the third quarter of 2009 representing two different revenue streams from the Shire collaboration agreement. Upon signing the collaboration agreement, Amicus received an upfront payment of $50 million that had been recognized as revenue on a straight-line basis over 18 years from the date of the agreement. In the third quarter of 2009, Amicus recognized $0.7 million of the Shire upfront payment and $4.2 million of research revenue on reimbursed research and development costs.

The differences between U.S. GAAP and non U.S. GAAP financial results are itemized in Tables 2 and 3 and are primarily due to pre-tax stock
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... Oldsmar, FL (PRWEB) , ... June 30, 2015 , ... ... approximately 7.76% of Cryo-Cell’s currently outstanding common shares (including shares of unvested restricted stock). ... tender offer, the last sale price of Cryo-Cell’s shares reported on the OTCBB was ...
(Date:6/30/2015)...  Custom Computer Specialists, Inc. ("Custom"), a leading healthcare ... sponsors of the Primary Care Development Corporation,s ("PCDC") Corporate ... their support of PCDC,s mission to expand access to ... founding in 1993, PCDC has been a key force ... financed over 100 completed primary care projects, valued at ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... She has accepted the position of vice president of instruction at Chippewa Valley ... , “I greatly appreciated the opportunity to lead SIUE during the past three ...
(Date:6/29/2015)... , ... June 30, 2015 , ... This cutting edge ... Elmer machines. Featuring 12 distinct peaks, the WAV-8 is the world’s first cuvette-shaped, ... in spec deep into the NIR range. Previous spectrophotometer calibration standards, such as those ...
Breaking Biology Technology:Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3Custom Computer Specialists Announces Sponsorship Of The Primary Care Development Corporation's Corporate Circle 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 3
... EDMONTON , May 11 /PRNewswire/ ... focused on developing medical device,products for use in ... has,received regulatory concurrence from the United States Food ... Occlusin(R) 500 Artificial,Embolization Device (OCL 500) in the ...
... GeneLink, Inc. (OTC Bulletin Board: GNLK), a leading consumer genomics biotech ... , , , ... , , ... Q4 2009 Comparable quarter gross profit improvement over Q1 2009 of 37% Q1 ...
... Cumberland Pharmaceuticals Inc. ( CPIX) and Phebra Pty Ltd. ... approval for marketing and sale in Australia . Acetadote, an injectable ... Goods Administration (TGA), the government agency responsible for regulating drugs and medical ... , , ...
Cached Biology Technology:IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S. 2IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S. 3GeneLink Reports First Quarter Gains 2Acetadote(R) Approved in Australia for Treatment of Acetaminophen Poisoning 2Acetadote(R) Approved in Australia for Treatment of Acetaminophen Poisoning 3Acetadote(R) Approved in Australia for Treatment of Acetaminophen Poisoning 4Acetadote(R) Approved in Australia for Treatment of Acetaminophen Poisoning 5
(Date:6/16/2015)... Fingerprint Cards (FPC) raises the revenue ... amount to at least 340 MSEK to that it will ... in market growth and orders received the revenue guidance for ... for 2015 will exceed 1,500 MSEK to an updated guidance ... Due to receipt of orders of touch fingerprint ...
(Date:6/15/2015)... NEW YORK , June 15, 2015 ... released today from Telstra reveals the majority of US consumers ... recognise them via biometrics, such as fingerprint and voiceprint, instead ... usernames. According to Telstra,s " Mobile Identity   ... " report, with smartphones now the primary channel ...
(Date:6/12/2015)... 12, 2015  Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, announced the ... electronically capture, analyze and identify participants of a ... This system can: , ... and subsequent sign-on process is actually the person ...
Breaking Biology News(10 mins):Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2
... species of bacteria with cholesterol-busting properties has been discovered ... Dr Oliver Drzyzga and colleagues isolated the new bug, ... findings are reported in the current issue of the ... A steroid found in all body tissues, cholesterol ...
... Through sophisticated statistical analyses and advanced computer ... genomic patterns of human population structure around ... insights into the history of human evolution, ... populations, and the relationships among populations. ...
... By snipping off parts of male genitalia and reducing ... researchers induced a suite of changes in female reproduction, ... attempts by the females. "To the best of our ... female choice following experimental manipulation of both male and ...
Cached Biology News:Researchers gain genome-wide insights into patterns of the world's human population structures 2Researchers gain genome-wide insights into patterns of the world's human population structures 3
Purified anti-SOCS3...
Tumor Suppressor Sampler Kit 10 mu g each...
AMAP Multi Site-directed Mutagenesis Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: dry ice...
Umbilical cord blood eosinophils, For immunohistochemistry (IHC)...
Biology Products: